Bavituximab

Drug Profile

Bavituximab

Alternative Names: 3G4; Anti-phosphatidylserine monoclonal antibody 3G4; Anti-phospholipid monoclonal antibody 3G4; Anti-PS MAb 3G4; Monoclonal antibody 3G4; Tarvacin

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Peregrine Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Immunovaccine; National Comprehensive Cancer Network; Peregrine Pharmaceuticals; University of Arizona; University of Texas Southwestern Medical Center
  • Class Adjuvants; Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I/II Hepatocellular carcinoma
  • Preclinical Brain cancer; Solid tumours
  • Suspended Breast cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer
  • No development reported Hepatitis C; HIV infections; Viral haemorrhagic fevers
  • Discontinued Influenza virus infections; Prostate cancer

Most Recent Events

  • 04 Apr 2017 Phase-I/II clinical trials in Hepatocellular carcinoma (Combination therapy, Late-stage disease) in USA (IV)
  • 04 Apr 2017 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Mid-stage disease) in India, Georgia, Russia, Ukraine, USA (IV)
  • 04 Apr 2017 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Georgia, India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top